Curaleaf Holdings announced Tuesday it will pursue a hostile takeover of Aurora Cannabis, offering a mix of cash and stock that values the struggling Canadian producer at approximately $2.3 billion.
The multistate operator disclosed plans to purchase all outstanding Aurora shares at a premium to the company's current trading price. Curaleaf is offering 0.1 of its subordinate voting shares plus $0.25 in cash for each Aurora share, representing a 30% premium to Aurora's 30-day volume-weighted average price.
The move marks one of the few instances where a U.S. cannabis operator has attempted to acquire a Canadian licensed producer since legalization north of the border in 2018. Most cross-border M&A activity has flowed in the opposite direction, with Canadian firms acquiring U.S. assets during the 2018-2019 investment boom.
The Numbers
Aurora Cannabis has seen its market value collapse from a 2019 peak of roughly $12 billion to around $1.8 billion before Curaleaf's offer. The Edmonton-based company reported a net loss of C$96.3 million in its most recent quarter and has undergone multiple restructurings to stem cash burn.
Curaleaf, by contrast, generated $343 million in revenue last quarter and maintains operations in 17 U.S. states. The Wakefield, Massachusetts-based MSO holds roughly $400 million in cash and equivalents on its balance sheet.
The hostile approach suggests Aurora's board has already rebuffed preliminary overtures. Curaleaf must now take its case directly to Aurora shareholders, who have watched the stock decline more than 95% from its 2019 highs.
Strategic Rationale
For Curaleaf, the deal would provide immediate access to international medical cannabis markets where Aurora maintains distribution agreements in 25 countries. Aurora's EU-GMP certified production facilities in Denmark and Germany could prove valuable as European medical markets expand.
The acquisition would also bring Aurora's 2.5 million square feet of licensed production capacity under Curaleaf's control, though much of that space sits idle following Aurora's 2020-2021 facility closures and workforce reductions.
Market watchers note the timing coincides with growing M&A activity in the cannabis sector as companies consolidate to achieve profitability. Five deals worth over $100 million have been announced in North America this year, compared to just two in all of 2023.
Regulatory Hurdles
The deal faces significant regulatory complexity. U.S. cannabis operators remain federally illegal and cannot list on major U.S. exchanges, while Aurora trades on both NASDAQ and the Toronto Stock Exchange. Curaleaf's subordinate voting shares trade only on the TSX and over-the-counter markets.
Canadian investment rules require approval from the federal government for foreign takeovers of companies deemed strategic assets. Aurora's international medical cannabis licenses and pharmaceutical partnerships could trigger enhanced scrutiny under the Investment Canada Act.
Additionally, Curaleaf would need to navigate conflicting regulatory frameworks. Aurora's operations in federally legal markets like Canada and Germany differ substantially from Curaleaf's state-licensed U.S. business model.
What's Next
Curaleaf has not yet filed formal takeover documents with Canadian securities regulators. The company must submit a detailed offer circular within 105 days of announcing its intention to make a bid.
Aurora's board will likely issue a formal response within two weeks, potentially including a fairness opinion from independent financial advisors. The company could also seek a white knight bidder or implement defensive measures, though Canadian takeover rules limit such tactics once a formal bid is launched.
Shareholders will ultimately decide the outcome through a tender process. Curaleaf needs acceptance from holders of at least 50% of Aurora's outstanding shares, plus approval from two-thirds of shares actually tendered.
The deal's fate may hinge on whether institutional investors see more value in Aurora's restructuring plan or Curaleaf's integration strategy. Several major Canadian pension funds hold significant Aurora positions and have historically resisted hostile takeovers in the cannabis sector.
This article is based on original reporting by ganjapreneur.com.
